← Back to patent-cliff list
Zongertinib
Tier C — Watch / tradeZongertinib
Boehringer Ingelheim International Gmbh
Originator
2025
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：HER2
Brand：HERNEXEOS
Indications (approved)：Non-small cell lung cancer
Regional status
US
Approved
2025-08-08
EU
Phase III
2024-02-09
China
Approved
2025-08-26
Japan
Approved
2025-09-19
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Zongertinib?
Approved indications include: Non-small cell lung cancer.
When does the Zongertinib patent expire?
No public expiry year is available for Zongertinib yet; this page updates once verified.
How do I get a quote for Zongertinib intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-01